M1 muscarinic receptor Inhibitors
1 drugsAbout M1 muscarinic receptor
The M1 muscarinic receptor, also known as the cholinergic receptor muscarinic 1, binds acetylcholine and triggers intracellular signaling, playing a crucial role in the central and peripheral nervous systems.
While there is currently no genetic evidence directly linking the M1 muscarinic receptor to specific diseases, its involvement in cognitive function, gastric acid secretion, and smooth muscle contraction makes it a potential therapeutic target.
Currently, one FDA-approved drug, darifenacin, targets the M1 muscarinic receptor as a small molecule for an 'other' therapeutic area, approved in 2017 by Macleods Pharms LTD.
Top M1 muscarinic receptor Drugs
Only one company, Macleods Pharms LTD, has an approved drug for this target.
Low competition indicates a potential market opportunity for new entrants.
M1 muscarinic receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets M1 muscarinic receptor, using small molecule modality.
The modality landscape suggests an opportunity for novel modalities like antibodies or biologics.
M1 muscarinic receptor Clinical Trials 8 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on M1 muscarinic receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 2 | 0 | 1 | 1 | 0% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 3 | 2 | 1 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
M1 muscarinic receptor Drug Approval Timeline (2017 - 2017)
The first and most recent drug approval was in 2017, with darifenacin.
The approval timeline indicates a potentially unsaturated market with room for innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 8 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on M1 muscarinic receptor. A trial counts if an approved drug acting on M1 muscarinic receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.